Global and United States Myelodysplastic Syndrome (MDS) Drugs Market Report & Forecast 2024-2031

Report ID: 1835339 | Published Date: Jan 2025 | No. of Page: 65 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Myelodysplastic Syndrome (MDS) Drugs Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Myelodysplastic Syndrome (MDS) Drugs Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size for the Year 2017-2028
        1.2.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Size for the Year 2017-2028
    1.3 Myelodysplastic Syndrome (MDS) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Myelodysplastic Syndrome (MDS) Drugs in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Myelodysplastic Syndrome (MDS) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Myelodysplastic Syndrome (MDS) Drugs Market Dynamics
        1.4.1 Myelodysplastic Syndrome (MDS) Drugs Industry Trends
        1.4.2 Myelodysplastic Syndrome (MDS) Drugs Market Drivers
        1.4.3 Myelodysplastic Syndrome (MDS) Drugs Market Challenges
        1.4.4 Myelodysplastic Syndrome (MDS) Drugs Market Restraints
    1.5 Study Objectives
    1.6 Years Considered
2 Myelodysplastic Syndrome (MDS) Drugs by Type
    2.1 Myelodysplastic Syndrome (MDS) Drugs Market Segment by Type
        2.1.1 Hypomethylating Agents
        2.1.2 Immunomodulatory Drugs
        2.1.3 Anti-anemics
    2.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2017, 2022 & 2028)
    2.3 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2017-2028)
    2.4 United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2017, 2022 & 2028)
    2.5 United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2017-2028)
3 Myelodysplastic Syndrome (MDS) Drugs by Application
    3.1 Myelodysplastic Syndrome (MDS) Drugs Market Segment by Application
        3.1.1 Original
        3.1.2 Generics
    3.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2017, 2022 & 2028)
    3.3 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2017-2028)
    3.4 United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2017, 2022 & 2028)
    3.5 United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2017-2028)
4 Global Myelodysplastic Syndrome (MDS) Drugs Competitor Landscape by Company
    4.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Company
        4.1.1 Top Global Myelodysplastic Syndrome (MDS) Drugs Companies Ranked by Revenue (2021)
        4.1.2 Global Myelodysplastic Syndrome (MDS) Drugs Revenue by Player (2017-2022)
    4.2 Global Myelodysplastic Syndrome (MDS) Drugs Concentration Ratio (CR)
        4.2.1 Myelodysplastic Syndrome (MDS) Drugs Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Myelodysplastic Syndrome (MDS) Drugs in 2021
        4.2.3 Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Myelodysplastic Syndrome (MDS) Drugs Headquarters, Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Myelodysplastic Syndrome (MDS) Drugs Headquarters and Area Served
        4.3.2 Global Myelodysplastic Syndrome (MDS) Drugs Companies Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Myelodysplastic Syndrome (MDS) Drugs Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Company
        4.5.1 Top Myelodysplastic Syndrome (MDS) Drugs Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Myelodysplastic Syndrome (MDS) Drugs Revenue by Players (2020, 2021 & 2022)
5 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region
    5.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2017-2028)
        5.2.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region: 2017-2022
        5.2.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth 2017-2028
        6.1.2 North America Myelodysplastic Syndrome (MDS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth 2017-2028
        6.3.2 Europe Myelodysplastic Syndrome (MDS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth 2017-2028
        6.4.2 Latin America Myelodysplastic Syndrome (MDS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE
7 Company Profiles
    7.1 Celgene
        7.1.1 Celgene Company Details
        7.1.2 Celgene Business Overview
        7.1.3 Celgene Myelodysplastic Syndrome (MDS) Drugs Introduction
        7.1.4 Celgene Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
        7.1.5 Celgene Recent Development
    7.2 Amgen
        7.2.1 Amgen Company Details
        7.2.2 Amgen Business Overview
        7.2.3 Amgen Myelodysplastic Syndrome (MDS) Drugs Introduction
        7.2.4 Amgen Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
        7.2.5 Amgen Recent Development
    7.3 Otsuka
        7.3.1 Otsuka Company Details
        7.3.2 Otsuka Business Overview
        7.3.3 Otsuka Myelodysplastic Syndrome (MDS) Drugs Introduction
        7.3.4 Otsuka Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
        7.3.5 Otsuka Recent Development
    7.4 Takeda
        7.4.1 Takeda Company Details
        7.4.2 Takeda Business Overview
        7.4.3 Takeda Myelodysplastic Syndrome (MDS) Drugs Introduction
        7.4.4 Takeda Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
        7.4.5 Takeda Recent Development
8 Research Findings and Conclusion
9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Myelodysplastic Syndrome (MDS) Drugs Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Myelodysplastic Syndrome (MDS) Drugs Market Trends
    Table 3. Myelodysplastic Syndrome (MDS) Drugs Market Drivers
    Table 4. Myelodysplastic Syndrome (MDS) Drugs Market Challenges
    Table 5. Myelodysplastic Syndrome (MDS) Drugs Market Restraints
    Table 6. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Myelodysplastic Syndrome (MDS) Drugs Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Myelodysplastic Syndrome (MDS) Drugs Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Player, 2017-2022
    Table 13. Global Myelodysplastic Syndrome (MDS) Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Myelodysplastic Syndrome (MDS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Drugs as of 2021)
    Table 15. Top Players of Myelodysplastic Syndrome (MDS) Drugs in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Myelodysplastic Syndrome (MDS) Drugs Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Myelodysplastic Syndrome (MDS) Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Myelodysplastic Syndrome (MDS) Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Myelodysplastic Syndrome (MDS) Drugs Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Myelodysplastic Syndrome (MDS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Myelodysplastic Syndrome (MDS) Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Myelodysplastic Syndrome (MDS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Myelodysplastic Syndrome (MDS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Celgene Company Details
    Table 31. Celgene Business Overview
    Table 32. Celgene Myelodysplastic Syndrome (MDS) Drugs Product
    Table 33. Celgene Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million)
    Table 34. Celgene Recent Development
    Table 35. Amgen Company Details
    Table 36. Amgen Business Overview
    Table 37. Amgen Myelodysplastic Syndrome (MDS) Drugs Product
    Table 38. Amgen Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million)
    Table 39. Amgen Recent Development
    Table 40. Otsuka Company Details
    Table 41. Otsuka Business Overview
    Table 42. Otsuka Myelodysplastic Syndrome (MDS) Drugs Product
    Table 43. Otsuka Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million)
    Table 44. Otsuka Recent Development
    Table 45. Takeda Company Details
    Table 46. Takeda Business Overview
    Table 47. Takeda Myelodysplastic Syndrome (MDS) Drugs Product
    Table 48. Takeda Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022) & (US$ Million)
    Table 49. Takeda Recent Development
    Table 50. Research Programs/Design for This Report
    Table 51. Key Data Information from Secondary Sources
    Table 52. Key Data Information from Primary Sources
List of Figures
    Figure 1. Myelodysplastic Syndrome (MDS) Drugs Product Picture
    Figure 2. Global Myelodysplastic Syndrome (MDS) Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Myelodysplastic Syndrome (MDS) Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. United States Myelodysplastic Syndrome (MDS) Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Myelodysplastic Syndrome (MDS) Drugs Market Size 2017-2028 (US$ Million)
    Figure 6. United States Myelodysplastic Syndrome (MDS) Drugs Market Share in Global 2017-2028
    Figure 7. Myelodysplastic Syndrome (MDS) Drugs Report Years Considered
    Figure 8. Product Picture of Hypomethylating Agents
    Figure 9. Product Picture of Immunomodulatory Drugs
    Figure 10. Product Picture of Anti-anemics
    Figure 11. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Type in 2022 & 2028
    Figure 12. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2017-2028) & (US$ Million)
    Figure 13. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Type (2017-2028)
    Figure 14. United States Myelodysplastic Syndrome (MDS) Drugs Market Share by Type in 2022 & 2028
    Figure 15. United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2017-2028) & (US$ Million)
    Figure 16. United States Myelodysplastic Syndrome (MDS) Drugs Market Share by Type (2017-2028)
    Figure 17. Product Picture of Original
    Figure 18. Product Picture of Generics
    Figure 19. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Application in 2022 & 2028
    Figure 20. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2017-2028) & (US$ Million)
    Figure 21. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Application (2017-2028)
    Figure 22. United States Myelodysplastic Syndrome (MDS) Drugs Market Share by Application in 2022 & 2028
    Figure 23. United States Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. United States Myelodysplastic Syndrome (MDS) Drugs Market Share by Application (2017-2028)
    Figure 25. North America Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 26. U.S. Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 27. Canada Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 28. Europe Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. Germany Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. France Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. U.K. Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. Italy Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Russia Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 35. China Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Japan Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. South Korea Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. India Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Australia Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Taiwan Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Thailand Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Malaysia Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Philippines Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 46. Mexico Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Brazil Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Argentina Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 50. Turkey Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Saudi Arabia Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. UAE Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Celgene Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
    Figure 54. Amgen Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
    Figure 55. Otsuka Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
    Figure 56. Takeda Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2017-2022)
    Figure 57. Bottom-up and Top-down Approaches for This Report
    Figure 58. Data Triangulation
    Figure 59. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Celgene
Amgen
Otsuka
Takeda
Frequently Asked Questions
Myelodysplastic Syndrome (MDS) Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Myelodysplastic Syndrome (MDS) Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Myelodysplastic Syndrome (MDS) Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports